Literature DB >> 8081368

Germline mutations in the neurofibromatosis type 2 tumour suppressor gene.

D Bourn1, S A Carter, S Mason, D Gareth, R Evans, T Strachan.   

Abstract

The recent identification of the NF2 tumour suppressor gene has enabled large scale screening for pathological mutations in the gene. We have sought germline mutations in the NF2 gene by SSCP and heteroduplex analysis of cDNA and genomic DNA samples followed by cloning and sequencing of mutant alleles. In the present report we describe 11 putative pathological mutations, including five nonsense mutations, three short insertions or deletions causing frameshifts and three missense mutations. Most stop mutations and frameshift mutations were found in individuals expressing a severe phenotype while one of the three missense mutations was associated with a mild phenotype. Four unrelated NF2 patients of the 93 tested were found to have identical nonsense mutations caused by a C to T transition (C169) in a CpG dinucleotide, which is a potential mutational hotspot in the NF2 tumour suppressor gene.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8081368     DOI: 10.1093/hmg/3.5.813

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  21 in total

1.  Screening for mutations in the neurofibromatosis type 2 (NF2) gene in sporadic meningiomas.

Authors:  L R De Vitis; A Tedde; F Vitelli; F Ammannati; P Mennonna; U Bigozzi; E Montali; L Papi
Journal:  Hum Genet       Date:  1996-05       Impact factor: 4.132

2.  Analysis of the neurofibromatosis type 2 gene in different human tumors of neuroectodermal origin.

Authors:  L R De Vitis; A Tedde; F Vitelli; F Ammannati; P Mennonna; P Bono; B Grammatico; P Grammatico; P Radice; U Bigozzi; E Montali; L Papi
Journal:  Hum Genet       Date:  1996-05       Impact factor: 4.132

3.  Differential diagnosis of type 2 neurofibromatosis: molecular discrimination of NF2 and sporadic vestibular schwannomas.

Authors:  C L Wu; N Thakker; W Neary; G Black; R Lye; R T Ramsden; A P Read; D G Evans
Journal:  J Med Genet       Date:  1998-12       Impact factor: 6.318

4.  Fluorescence-based mutation detection. Single-strand conformation polymorphism analysis (F-SSCP).

Authors:  J S Ellison
Journal:  Mol Biotechnol       Date:  1996-02       Impact factor: 2.695

Review 5.  Neurofibromatosis type 2.

Authors:  D G Evans; M Sainio; M E Baser
Journal:  J Med Genet       Date:  2000-12       Impact factor: 6.318

6.  Eleven novel mutations in the NF2 tumour suppressor gene.

Authors:  D Bourn; G Evans; S Mason; S Tekes; L Trueman; T Strachan
Journal:  Hum Genet       Date:  1995-05       Impact factor: 4.132

7.  Functional analysis of the neurofibromatosis type 2 protein by means of disease-causing point mutations.

Authors:  R P Stokowski; D R Cox
Journal:  Am J Hum Genet       Date:  2000-03       Impact factor: 11.025

8.  A 163-bp deletion in the neurofibromatosis 2 (NF2) gene associated with variant phenotypes [corrected].

Authors:  L Kluwe; S M Pulst; J Köppen; V F Mautner
Journal:  Hum Genet       Date:  1995-04       Impact factor: 4.132

9.  Lack of NF1 expression in a sporadic schwannoma from a patient without neurofibromatosis.

Authors:  D H Gutmann; I Silos-Santiago; R T Geist; M Daras; J L Rutkowski
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

10.  Identification of three neurofibromatosis type 2 (NF2) gene mutations in vestibular schwannomas.

Authors:  J Sainz; K Figueroa; M E Baser; S M Pulst
Journal:  Hum Genet       Date:  1996-01       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.